Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow

International Journal of Cardiology

Volumn 187, Issue 1, 2015, Pages 511-516

  Bouleti, Claire ^a,b,c,d,e   Mathivet, Thomas ^a,b,c   Serfaty, Jean Michel ^d   Vignolles, Nicolas ^f,g   Berland, Elodie ^a,b,c   Monnot, Catherine ^a,b,c,d,e   Cluzel, Philippe ^g   Steg, Philippe Gabriel ^d,e   Montalescot, Gilles ^f,g   Germain, Stéphane ^a,b,c,h,i  

^a l'alimentation et l'Environnement   (France)

^b CNRS   (France)

^c INSERM   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Institut de Cardiologie (AP HP) ACTION Study Group   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h Equipe Labellisee e Ligue Nationale contre le Cancer   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

Acute myocardial infarction; Endothelium; No reflow; Vascular biology

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPOIETIN LIKE 4; C REACTIVE PROTEIN; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; GADOTERATE MEGLUMINE; HEPARIN; PROTEIN; TROPONIN T; UNCLASSIFIED DRUG; ANGIOPOIETIN; ANGPTL4 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; EXPERIMENTAL MODEL; FEMALE; HEART INFARCTION SIZE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOGISTIC REGRESSION ANALYSIS; MALE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYMPTOM; THROMBUS; ADVERSE EFFECTS; AGED; ANIMAL; ANIMAL MODEL; BLOOD; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; MOUSE; MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ODDS RATIO; PATHOPHYSIOLOGY; PROCEDURES; STATISTICAL MODEL;

AGED; ANGIOPOIETINS; ANIMALS; C-REACTIVE PROTEIN; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MODELS, ANIMAL; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; ODDS RATIO; PATIENT ADMISSION; PERCUTANEOUS CORONARY INTERVENTION; TROPONIN T;

EID: 84929378490     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.263     Document Type: Article

References (39)

1. E.C. Keeley, J.A. Boura, C.L. Grines, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials, Lancet 361 (2003) 13-20.
2. D.J. Hausenloy, H. Erik Botker, G. Condorelli, et al., Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology, Cardiovasc. Res. 98 (2013) 7-27.
3. G.M. Frohlich, P. Meier, S.K. White, et al., Myocardial reperfusion injury: looking beyond primary PCI, Eur. Heart J. 34 (2013) 1714-1722.
4. H. Ito, A. Okamura, K. Iwakura, et al., Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction, Circulation 93 (1996) 1993-1999.
5. G. Niccoli, R.K. Kharbanda, F. Crea, A.P. Banning, No-reflow: again prevention is better than treatment, Eur. Heart J. 31 (2010) 2449-2455.
6. B.G. Schwartz, R.A. Kloner, Coronary no reflow, J. Mol. Cell. Cardiol.52 (2012) 873-882.
7. R. Berg, C. Buhari, Treating and preventing no reflow in the cardiac catheterization laboratory, Curr. Cardiol. Rev. 8 (2012) 209-214.
8. G. Heusch, Cardioprotection: chances and challenges of its translation to the clinic, Lancet 381 (2013) 166-175.
9. M. Murakami, M. Simons, Regulation of vascular integrity, J. Mol. Med. 87 (2009) 571-582.
10. G. Heusch, P. Kleinbongard, A. Skyschally, et al., The coronary circulation in cardioprotection: more than just one confounder, Cardiovasc. Res. 94 (2012) 237-245.
11. S.H. Rezkalla, R.A. Kloner, No-reflow phenomenon, Circulation 105 (2002) 656-662.
12. G. Niccoli, S. Giubilato, E. Russo, et al., Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention, Eur. Heart J. 29 (2008) 1843-1850.
13. S.H. Lee, P.L. Wolf, R. Escudero, et al., Early expression of angiogenesis factors in acute myocardial ischemia and infarction, N. Engl. J. Med. 342 (2000) 626-633.
14. G. Pannitteri, E. Petrucci, U. Testa, Coordinate release of angiogenic growth factors after acute myocardial infarction: evidence of a two-wave production, J. Cardiovasc. Med. (Hagerstown) 7 (2006) 872-879.
15. S. Weis, S. Shintani, A. Weber, et al., Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction, J. Clin. Invest. 113 (2004) 885-894.
16. S.M. Weis, D.A. Cheresh, Pathophysiological consequences of VEGF-induced vascular permeability, Nature 437 (2005) 497-504.
17. S. Le Jan, C. Amy, A. Cazes, et al., Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma, Am. J. Pathol. 162 (2003) 1521-1528.
18. A. Galaup, E. Gomez, R. Souktani, et al., Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4, Circulation 125 (2012) 140-149.
19. K.C. Wu, E.A. Zerhouni, R.M. Judd, et al., Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction, Circulation 97 (1998) 765-772.
20. R. Nijveldt, A.M. Beek, A. Hirsch, et al., Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury, J. Am. Coll. Cardiol. 52 (2008) 181-189.
21. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group, N. Engl. J. Med. 312 (1985) 932-936.
22. C. Bouleti, T. Mathivet, B. Coqueran, et al., Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke, Eur. Heart J. 34 (2013) 3657-3668.
23. G.K. Lund, A. Stork, M. Saeed, et al., Acute myocardial infarction: evaluation with first-pass enhancement and delayed enhancement MR imaging compared with 201Tl SPECT imaging, Radiology 232 (2004) 49-57.
24. R.J. Kim, D.S. Fieno, T.B. Parrish, et al., Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function, Circulation 100 (1999) 1992-2002.
25. V. Hombach, O. Grebe, N. Merkle, et al., Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging, Eur. Heart J. 26 (2005) 549-557.
26. S. Orn, C. Manhenke, O.J. Greve, et al., Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention, Eur. Heart J. 30 (2009) 1978-1985.
27. A. Xu, M.C. Lam, K.W. Chan, et al., Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6086-6091.
28. G. Tarantini, L. Cacciavillani, F. Corbetti, et al., Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance, J. Am. Coll. Cardiol. 46 (2005) 1229-1235.
29. J. Bogaert, M. Kalantzi, F.E. Rademakers, et al., Determinants and impact of microvascular obstruction in successfully reperfused ST-segment elevation myocardial infarction. Assessment by magnetic resonance imaging, Eur. Radiol. 17 (2007) 2572-2580.
30. J. Vicente, N. Mewton, P. Croisille, et al., Comparison of the angiographic myocardial blush grade with delayed-enhanced cardiac magnetic resonance for the assessment of microvascular obstruction in acute myocardial infarctions, Catheter. Cardiovasc. Interv. 74 (2009) 1000-1007.
31. G. Sardella, M. Mancone, C. Bucciarelli-Ducci, et al., Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial, J. Am. Coll. Cardiol. 53 (2009) 309-315.
32. V. Bodi, J. Sanchis, J. Nunez, et al., Prognostic value of a comprehensive cardiac magnetic resonance assessment soon after a first ST-segment elevation myocardial infarction, JACC Cardiovasc. Imaging 2 (2009) 835-842.
33. J. Gavard, J.S. Gutkind, VE-cadherin and claudin-5: it takes two to tango, Nat. Cell Biol. 10 (2008) 883-885.
34. S. Yla-Herttuala, T.T. Rissanen, I. Vajanto, J. Hartikainen, Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine, J. Am. Coll. Cardiol. 49 (2007) 1015-1026.
35. N. van Bruggen, H. Thibodeaux, J.T. Palmer, et al., VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain, J. Clin. Invest. 104 (1999) 1613-1620.
36. S. Fichtlscherer, G. Rosenberger, D.H. Walter, et al., Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease, Circulation 102 (2000) 1000-1006.
37. T.H. Schindler, E.U. Nitzsche, M. Olschewski, et al., Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors, Circulation 110 (2004) 1069-1075.
38. K. Iwakura, H. Ito, S. Kawano, et al., Predictive factors for development of the noreflow phenomenon in patients with reperfused anterior wall acute myocardial infarction, J. Am. Coll. Cardiol. 38 (2001) 472-477.
39. G. Niccoli, G.A. Lanza, S. Shaw, et al., Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization, Eur. Heart J. 27 (2006) 1793-1798.